Abstract:We developed a custom-designed liposome carrier for codelivery of a potent immunogenic cell death (ICD) stimulus plus an inhibitor of the indoleamine 2,3-dioxygenase (IDO-1) pathway to establish a chemo-immunotherapy approach for solid tumors in syngeneic mice. The carrier was constructed by remote import of the anthraquinone chemotherapeutic agent, mitoxantrone (MTO), into the liposomes, which were further endowed with a cholesterol-conjugated indoximod (IND) prodrug in the lipid bilayer. For proof-of-principle testing, we used IV injection of the MTO/IND liposome in a CT26 colon cancer model to demonstrate the generation of a robust immune response, characterized by the appearance of ICD markers (CRT and HMGB-1) as well as evidence of cytotoxic cancer cell death, mediated by perforin and granzyme B. Noteworthy, the cytotoxic effects involved natural killer (NK) cell, which suggests a different type of ICD response. The immunotherapy response was significantly augmented by codelivery of the IND prodrug, which induced additional CRT expression, reduced number of Foxp3+ Treg, and increased perforin release, in addition to extending animal survival beyond the effect of an MTO-only liposome. The outcome reflects the improved pharmacokinetics of MTO delivery to the cancer site by the carrier. In light of the success in the CT26 model, we also assessed the platform efficacy in further breast cancer (EMT6 and 4T1) and renal cancer (RENCA) models, which overexpress IDO-1. Encapsulated MTO delivery was highly effective for inducing chemo-immunotherapy responses, with NK participation, in all tumor models. Moreover, the growth inhibitory effect of MTO was enhanced by IND codelivery in EMT6 and 4T1 tumors. All considered, our data support the use of encapsulated MTO delivery for chemo-immunotherapy, with the possibility to boost the immune response by codelivery of an IDO-1 pathway inhibitor.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c05194?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c05194</a>.Additional figures and results, e.g., NMR, MS, HPLC spectra, and representative IHC staining, as described in the text (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c05194/suppl_file/nn0c05194_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

Enhancement of Microglia Functions by Developed Nano‐Immuno‐Synergist to Ameliorate Immunodeficiency for Malignant Glioma Treatment

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy

Doxorubicin-Isoniazid Conjugate Regulates Immune Response and Tumor Microenvironment to Enhance Cancer Therapy

Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity

Targeting monoamine oxidase A for T cell–based cancer immunotherapy

Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment

Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy

Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators

ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death

Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy

Multifunctional Nanomodulators Regulate Multiple Pathways to Enhance Antitumor Immunity

Enhancement of antitumor immunotherapy using mitochondria-targeted cancer cell membrane-biomimetic MOF-mediated sonodynamic therapy and checkpoint blockade immunotherapy

Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression

Pegylated liposomal mitoxantrone modulates tumor immune landscape to boost PD-L1 blockade therapy

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors

In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy

Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy

A miRNA-based gene therapy nanodrug synergistically enhances pro-inflammatory antitumor immunity against melanoma